Skip to content

Phase II Clinical Trial of Qingke Pingchuan Granules in Treating Acute Bronchitis in Children

A randomized, double-blind, parallel controlled, multi-center clinical trial of the effectiveness and safety of Qingke Pingchuan Granules in the treatment of children with acute bronchitis (phlegm-heat stagnation lung syndrome)

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100044329
Enrollment
Unknown
Registered
2021-03-16
Start date
2021-05-01
Completion date
Unknown
Last updated
2021-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute bronchitis in children

Interventions

Sponsors

Shanghai Traditional Chinese Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 14 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria of western medicine for acute bronchitis in children; 2. TCM syndrome differentiation accords with phlegm-heat stagnation syndrome; 3. 6 years old <= age <= 14 years old, no gender limit; 4. Course of disease <= 48h; 5. Parents or guardians voluntarily agree and sign the informed consent form, and the children = 8 years old participate in the informed consent and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Severe bronchitis and pneumonia are difficult to distinguish in the early stage; 2. Suffer from acute infectious diseases such as measles, whooping cough and influenza; 3. Children with acute upper respiratory tract infection, bronchial asthma, bronchiolitis, bronchopneumonia and other respiratory diseases; 4. Children with acute attacks of chronic bronchitis; 5. The total number of white blood cells > 12 x 10^9/L, and the percentage of neutrophils > 70%; 6. Children with malnutrition and immunodeficiency; 7. Children whose body temperature exceeds 38.0 degrees C; 8. Liver function test values (ALT, AST) > upper limit of normal value, blood creatinine > upper limit of normal value; 9. Those who are allergic to the test drug or its components; 10. Children who have used antibiotics, cough-reducing and phlegm-resolving medicines and other Chinese and Western medicines that have an impact on cough within 24 hours before treatment; 11. Combined with serious primary diseases such as severe heart, liver, kidney, digestive and hematopoietic system; 12. According to the judgment of the investigator, there are other diseases or conditions that reduce the possibility of enrollment or complicate enrollment, such as unstable living environment, inconvenient transportation, etc. that may easily cause loss to follow-up.

Design outcomes

Primary

MeasureTime frame
Clinical recovery time of disease ;

Secondary

MeasureTime frame
Cough disappearance time, once every 24h (1d) after treatment ;Bronchitis severity score, baseline and treatment endpoint records ;TCM syndrome score, baseline, 3 days of treatment and treatment endpoint record ;Single symptoms (cough, expectoration, phlegm in the throat, shortness of breath/wheezing, fever, sore throat, thirst, red face, short urine, dry stool) disappearance rate, treatment endpoint evaluation ;Complication rate, antibiotic usage rate, treatment endpoint evaluation ;Efficacy of TCM syndromes, treatment endpoint evaluation;

Countries

China

Contacts

Public ContactZhang Jie

Lei Yunshang Pharmaceutical Group Co., Ltd.

zhangjie@lys.cn+86 13122828591

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026